BACKGROUND
Cystic Fibrosis (CF) is a genetic disorder that affects approximately 100,000 individuals worldwide, causing severe health issues, particularly in the lungs. The condition is the result of mutations in the CFTR gene, which is responsible for producing a protein that regulates the movement of chloride and bicarbonate across cell membranes. When this protein is faulty, it leads to the accumulation of thick mucus in the lungs, resulting in breathing difficulties and an increased risk of severe lung infections.
These infections, often caused by bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus, are a major cause of illness and death in CF patients. More recently, less common pathogens, such as non-tuberculous mycobacteria, have also been found in these patients' lungs, posing additional treatment challenges. Understanding the impact of these infections on the immune response in CF patients is crucial, as it may pave the way for improved treatments and enhance the quality of life for those affected by this chronic condition.
SUMMARY OF TECHNOLOGY
OSU researchers have created a technology that focuses on eliminating senescent cells, which is an innovative approach proven to significantly enhance the body's ability to combat severe lung infections, such as those caused by Mycobacterium abscessus in Cystic Fibrosis (CF) patients. By specifically targeting aging immune cells that weaken the body's defense response, this technology improves bacterial clearance and reduces tissue damage related to chronic infections. This offers new opportunities for more effective treatments that can improve the quality of life for patients with CF and other severe respiratory diseases.
POTENTIAL AREAS OF APPLICATION
- Host-directed treatment for cystic fibrosis patients with lung infections or cystic fibrosis-related aging.
- Potential for restoring immune function and tissue support in CF patients and in various degenerative conditions.
- Can be applied to other chronic respiratory diseases to improve patient outcomes by targeting senescent immune cells
MAIN ADVANTAGES
- Increase the treatment efficacy.
- Decrease lung damage.
- Enhance the immune response and reduce chronic bacterial infections.
STAGE OF DEVELOPMENT
CONTACT: Please contact the Office of Technology Commercialization (InnovationPortal@okstate.edu) for more information.